Anxiolytics

Global Nicotine Gum Market Trajectory & Analytics Report 2020-2027 Featuring Cambrex, Fertin Pharma, GlaxoSmithKline, Johnson & Johnson, Perrigo, Pfizer, Reynolds American - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 9, 2020
Retail, Other Retail, Psychoactive drugs, Smoking cessation, Articles, Nicotinic agonists, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Analytics

The "Nicotine Gum - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nicotine Gum - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • 2 mg, one of the segments analyzed in the report, is projected to grow at a 3.4% CAGR to reach US$3.5 Billion by the end of the analysis period.
  • This segment currently accounts for a 27% share of the global Nicotine Gum market.
  • The report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.

Unintended consequences: New regulations must protect youth while maintaining access to harm reduction for adult smokers

Retrieved on: 
Monday, November 30, 2020
Psychoactive drugs, Electronic cigarettes, Nicotinic agonists, Smoking cessation, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine, Tobacco, Electronic cigarette, Positions of medical organizations on electronic cigarettes

However, as demonstrated in Ontario and British Columbia the problem is not solely high nicotine concentrations but unrestricted access to these products.

Key Points: 
  • However, as demonstrated in Ontario and British Columbia the problem is not solely high nicotine concentrations but unrestricted access to these products.
  • There is a segment of adult smokers who rely on high nicotine products to prevent relapsing to combustible tobacco.
  • Which, by the QC gov't's own admission, meet a high standard of conformity in carding and denying access to minors.
  • As it stands, the policy recommendations proposed by QCTC would serve to benefit Big Tobacco and harm adult smokers.

TAAT Launch in Ohio Continues with Over 3.7 Million Ad Engagements and Strong Conversion Rate on TryTAAT; Final TAAT Pack Designs Revealed Featuring BOGO Promotion

Retrieved on: 
Friday, November 27, 2020
Psychoactive drugs, Nicotinic agonists, Branches of biology, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Teratogens, tAAt, Tobacco

TAAT remains on schedule to be available for purchase in Ohio in Q4 2020.

Key Points: 
  • TAAT remains on schedule to be available for purchase in Ohio in Q4 2020.
  • The Company has developed Beyond Tobacco, which is the base material of TAAT, containing no nicotine or tobacco.
  • As of this writing, approximately 13 million advertisements have been distributed and there have been over 3.7 million engagements with TAAT advertisements in this campaign.
  • These engagements have yielded several thousand confirmed requests for mailed samples of TAAT to addresses in the United States.

The Alprazolam Market 2020-2024- Featuring Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Endo International Plc, Among Others | Technavio

Retrieved on: 
Friday, November 6, 2020
General Health, Pharmaceutical, Health, Mental health, Alprazolam, Anxiolytics, Chloroarenes, Triazolobenzodiazepines, Business process, Market research

The alprazolam market is poised to grow by USD 90.33 mn during 2020-2024 progressing at a CAGR of 4% during the forecast period.

Key Points: 
  • The alprazolam market is poised to grow by USD 90.33 mn during 2020-2024 progressing at a CAGR of 4% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201106005311/en/
    Technavio has announced its latest market research report titled Global Alprazolam Market 2020-2024 (Graphic: Business Wire)
    The report on the alprazolam market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment.
  • This study identifies the use of alprazolam in new research areas as one of the prime reasons driving the alprazolam market growth during the next few years.

Advisory - Unauthorized nicotine buccal pouches may pose serious health risks

Retrieved on: 
Monday, November 2, 2020
Psychoactive drugs, Nicotinic agonists, Smoking cessation, Electronic cigarettes, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine, Tobacco, Cheek pouch, Buccal, Snus, Safety of electronic cigarettes

Products:Nicotine buccal pouches (placed between the gum and cheek), also known as tobacco-less nicotine pouches and oral nicotine pouches.

Key Points: 
  • Products:Nicotine buccal pouches (placed between the gum and cheek), also known as tobacco-less nicotine pouches and oral nicotine pouches.
  • Issue:Nicotine buccal pouches are unauthorized in Canada and may pose various serious health risks.
  • Health Canada is advising Canadians that nicotine buccal pouches (also known as tobacco-less nicotine pouches and oral nicotine pouches) have not been authorized in Canada.
  • For example, unauthorized nicotine buccal pouches may contain amounts of nicotine that exceed safe levels, or other ingredients not listed on the product label.

Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) Announces Launch of BidiTM Pouch, BidiTM Vapor’s Newest Smokeless Nicotine Product

Retrieved on: 
Thursday, October 29, 2020
Psychoactive drugs, Smoking cessation, Smoking, Alkaloids found in Erythroxylum coca, Anxiolytics, Nicotine

Engineered to provide a premium smokeless nicotine experience to its users, the Bidi Pouch is made from a tobacco-free nicotine formulation packed into an on-the-go pouch.

Key Points: 
  • Engineered to provide a premium smokeless nicotine experience to its users, the Bidi Pouch is made from a tobacco-free nicotine formulation packed into an on-the-go pouch.
  • BidiTM Vapor continues to expand its partnerships with nationally recognized convenience retail chains such as Circle K and Fas Mart.
  • It is a nicotine delivery product available in a small package for an on-the-go and smoke-free nicotine experience.
  • We are excited to introduce the BidiTM Pouch to adult consumers, said Niraj Patel, CEO of Kaival Brands.

ProvideGx® and Baxter Healthcare Secure the Supply of Critical Shortage Drug for COVID-19 Patients Requiring Ventilation

Retrieved on: 
Monday, October 26, 2020
Infectious diseases, Pharmaceutical, Health, Medical Supplies, Medicine, Health, Medical specialties, Respiratory therapy, Emergency medicine, Anxiolytics, Dexmedetomidine, Imidazoles, Mechanical ventilation, Coronavirus disease, Intensive care medicine, RECOVERY Trial

The drug has been on the U.S. Food and Drug Administrations (FDA) drug shortage list since April of 2020, when large numbers of COVID-19 patients were admitted to hospitals and received mechanical ventilation.

Key Points: 
  • The drug has been on the U.S. Food and Drug Administrations (FDA) drug shortage list since April of 2020, when large numbers of COVID-19 patients were admitted to hospitals and received mechanical ventilation.
  • However, severe cases of COVID-19 still require mechanical ventilation, and these cases are on the rise across the country.
  • The partnership between Premier and Baxter Healthcare will help stabilize the supply of one of these drugs for the benefit of the patients who are counting on ventilation to save their lives.
  • Dexmedetomidine is a front-line drug in our intensive care units, especially during this time when were dealing with higher numbers of hospitalized COVID-19 patients.

Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection

Retrieved on: 
Tuesday, October 20, 2020
Medical Supplies, Hospitals, FDA, Diabetes, Clinical trials, Other Health, Biotechnology, Managed care, Pharmaceutical, Health, Health, RTT, Clinical medicine, Medicine, Epilepsy, GABAA receptor positive allosteric modulators, Chloroarenes, Anxiolytics, Diazepam, Dravet syndrome, Epileptic seizure, Food and Drug Administration, Diazepam, Acute Repetitive Seizures, Xeris Pharmaceuticals, Inc.

Xeris XP-0863 was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet Syndrome.

Key Points: 
  • Xeris XP-0863 was previously granted orphan designations both for the treatment of acute repetitive seizures and for the treatment of Dravet Syndrome.
  • "The FDA's Fast Track designation highlights the clear unmet need in treating acute repetitive seizures with the preparations of diazepam available today and highlights our opportunity to dramatically improve care through the introduction of a ready-to-use injection formulation," said Paul R. Edick, Xeris Chairman and Chief Executive Officer.
  • As previously announced, complete results of the Phase 1b study were shared with the US FDA in an End-of-Phase 1 interaction.
  • The FDA provided feedback that Xeris drug development program for XP-0863 could advance directly into a Phase 3 registration study in both pediatric and adult patients with epilepsy.

Neurelis Announces Four Poster Presentations For The Joint Meeting Of The International Child Neurology Association And Child Neurology Society

Retrieved on: 
Friday, October 16, 2020
RTT, Drugs, Clinical medicine, Health, Anxiolytics, Benzodiazepines, Chloroarenes, Diazepam, Epileptic seizure, Epilepsy, Poster session

SAN DIEGO, Oct. 16, 2020 /PRNewswire/ -- Neurelis, Inc., announced today the company has four posters being presented at the 16th annual International Child Neurology Association Congress/49th annual Child Neurology Society Meeting.

Key Points: 
  • SAN DIEGO, Oct. 16, 2020 /PRNewswire/ -- Neurelis, Inc., announced today the company has four posters being presented at the 16th annual International Child Neurology Association Congress/49th annual Child Neurology Society Meeting.
  • Neurelis Chief Medical Officer Enrique Carrazana, M.D., said the poster presentations continue to validate the safety, pharmacokinetics, and tolerability of VALTOCO (diazepam nasal spray) in children with epilepsy aged 6 and older.
  • "The data continue to demonstrate that VALTOCO is an important treatment option for children with epilepsy suffering from seizure clusters,"Dr. Carrazana said.
  • The details for the poster presentations are as follows and are available online here ; type VALTOCO in search bar to view.

China Pregabalin Market Investigation Report, 2015-2020 & 2020-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 12, 2020
Pharmaceutical, Health, Other Health, Health, Amino acids, Analgesics, Calcium channel blockers, RTT, Anxiolytics, Pregabalin, Pfizer, Pharmaceutical industry, Chongqing

The "Investigation Report on the Chinese Pregabalin Market, 2020-2024 " report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on the Chinese Pregabalin Market, 2020-2024 " report has been added to ResearchAndMarkets.com's offering.
  • For example, the number of epileptics in China has exceeded 10 million and increases by 500 thousand every year.
  • Chongqing Succeway Pharmaceutical Co., Ltd.'s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer.
  • 2 Market Overview of Pregabalin in China, 2013-2018
    2.3 Investigation on Market Size of Pregabalin by Dosage Form in China, 2013-2018
    3 Investigation on Market Share of Major Pregabalin Manufacturers in China, 2013-2018
    3.3 Chongqing Succeway Pharmaceutical Co., Ltd.
    4 Sales Price of Pregabalin in China Market, 2019
    4.2.2 Chongqing Succeway Pharmaceutical Co., Ltd. (Lairuike)
    5 Prospects of Pregabalin Market, 2020-2024
    5.3 Forecast on Market Size of Pregabalin in China, 2020-2024
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005627/en/